Citi lowered the firm’s price target on Hims & Hers to $25 from $27 and keeps a Sell rating on the shares. The firm also added a “downside 30-day short-term view” on the shares. Citi expects Hims & Hers will reported “another significant beat and raise” quarter, largely driven by GLP-1 strength. However, this is unlikely to drive the stock higher, the analyst tells investors in a research note. Rather, Citi suspects the stock will trade down again on another sequential slowdown in core revenue with concerns around Hims & Hers’ personalized GLP-1 strategy, a weakening consumer, and potential pharma tariffs all weighing on investor sentiment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims and Hers Health call volume above normal and directionally bullish
- FDA alert on finasteride could elevate churn for Hims & Hers, says BofA
- Sell Rating Issued for Hims & Hers Health Amid FDA Concerns on Topical Finasteride
- Hims & Hers Stock (HIMS) Dips After FDA Flags Safety Concerns
- Hims & Hers Health COO Transition to Advisory Role